German pharmaceutical company BioNTech says it plans to create a state-of-the-art manufacturing site for its mRNA-based vaccines and other drugs in Singapore.
The company, which developed the first widely used coronavirus vaccine together with U.S. partner Pfizer, said Monday that it is also establishing a regional headquarters for Southeast Asia in the city-state.
BioNTech said the new manufacturing facility will boost the regional and global supply capacity of its products and ensure a rapid response to potential pandemic threats in the region.
The site, which could be operational by 2023, will have the capacity to produce “several hundred of million doses of mRNA-based vaccines depending on the specific vaccine,” the company said.